ClinicalTrials.gg
CompletedNCT04365933Updated Aug 25, 2022

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

A Phase 2 interventional study of EYP001a and Entecavir in Hepatitis B, Chronic, sponsored by Enyo Pharma. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-25.

Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
53rd of 59
20 · median 114
Started
2020
the only one that year
Phase 2
5 of 59
none open now
Registered
58th of 59
by date
Lead sponsor
2 of 59
Enyo Pharma

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 53rd largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 58th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is a multi centre, two parallel arm, randomized, open-label, Phase 2a experimental study of oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect when administered to non-treated (treatment naive or off treatment) chronic Hepatitis B (CHB) patients in combination with entecavir (ETV) and pegylated interferon alpha2a (peg-IFN). An experimental treatment period of 16 weeks will be followed by a 24 week maintenance period with ETV standard of care (SoC).

Read the detailed description

In total 30 eligible patients will be enrolled and randomized at approximately 7 study sites.

Patients will be randomized prior to study drug (EYP001a, ETV and peg-IFN) administration on Day 1 in the ratio of 1:1 into 2 treatment arms:

  • Arm 1: EYP001a QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW (± 3 days) (15 patients)
  • Arm 2: EYP001a QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW (± 3 days) (15 patients)

Patients enrolled in the study will be assessed as outpatients. Patient screening will occur no more than 37 days prior to the Day 1 visit. Eligible patients will undergo further assessments on Day 1 to qualify for study drug administration on Day 1.

The visits during the study are planned as below:

  • Screening visit: 5 weeks (37 days)
  • 16 weeks treatment period
  • 24 weeks maintenance period. During maintenance period patients are kept on ETV until the end of the trial at Week 40.
03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has given voluntary written before performance of any study related procedure.
  • Are treatment naive or without treatment for at least 60 days or 5 times the elimination half-life, whichever is longer.
  • Patient has CHB:

    1. HBV DNA ≥ 20,000 IU/mL for HBeAg positive and ≥2'000 for HBeAg negative and
    2. HBsAg ≥ 2.5 log10 IU/mL.
  • Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.
  • Patient is not of or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Is an employee of a clinical research organization, vendor, or Sponsor involved with this study.
  • Has known hepatocellular carcinoma or pancreaticobiliary disease.
  • Neutropenia (defined by two confirmed values during Screening period of \< 1500/μL).
  • Has Gilbert syndrome.
  • Shows evidence of worsening liver tests, defined as either a confirmed (2 assessments at least 3 days apart) increase > 2 or AST or an increase of > 1.5 × baseline value of TBL or associated with clinical signs or symptoms of liver impairment.
  • Has known or suspected non-CHB liver disease
  • History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.
  • Probable or possible F4 stage with a vibration controlled transient elastography (VCTE) > 11.7 kPa leads to exclusion
  • Has known history of alcohol abuse or daily heavy alcohol consumption
  • Has any of the following exclusionary laboratory results at screening:

    1. ALT > 2 × ULN, AST > 2 × ULN
    2. > 1.2 × ULN, (normal range is 0.8 to 1.2)
    3. count \< 100 G/L
    4. Estimated \< 50 mL/min/1.73m2 (the Modification of Diet in Renal Disease formula)
    5. Thyroid-stimulating hormone > 1.5 × ULN or abnormal free triiodothyronine or free thyroxine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Arm 1

    EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW

    Drug: EYP001a · Drug: Entecavir · Drug: Pegylated interferon alpha2a

  • Experimental
    Arm 2

    EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW

    Drug: EYP001a · Drug: Pegylated interferon alpha2a

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent adverse events

    Number of Treatment-emergent adverse events including serious adverse events

    Time frame: 16 weeks

  2. Measurement of HBsAg decline

    Measurement of HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment period

    Time frame: 16 weeks

Secondary outcomes

  1. Measurement of HBsAg decline

    Measurement of HBsAg decline (Δ log10)

    Time frame: 40 weeks

  2. Measurement of HBV-DNA decline

    Measurement of HBV-DNA decline (Δ log10)

    Time frame: 40 weeks

  3. Measurement of HBV-pgRNA decline

    Measurement of HBV-pgRNA decline (Δ log10)

    Time frame: 40 weeks

  4. Measurement of HBcrAg decline

    Measurement of HBcrAg decline (Δ log10)

    Time frame: 40 weeks

  5. Concentration of EYP001a - Pharmacokinetic

    Assessment of fasted plasma concentrations of EYP001a or any active metabolites using a validated liquid chromatography-mass spectrometry

    Time frame: 20 weeks

  6. Concentration of C4 - Pharmacodynamic biomarker

    Assessment of concentrations of plasma C4 (7α hydroxy 4 cholesten 3 one)

    Time frame: 40 weeks

  7. Concentration of FGF19 - Pharmacodynamic biomarker

    Assessment of concentrations of plasma FGF19 over time (Fibroblast Growth Factor 19)

    Time frame: 40 weeks

  8. Concentration of Bile Acids - Pharmacodynamic biomarker

    Assessment of concentrations over time of plasma Bile Acids (chenodeoxycholic acid, deoxycholic acid, lithocholic acid)

    Time frame: 40 weeks

07

Study locations

6 sites
  • ENYO PHARMA Investigative site HK01
    Hong Kong, Hong Kong
  • ENYO PHARMA Investigative site KR01
    Busan, Korea, Republic of
  • ENYO PHARMA Investigative site TW03
    Kaohsiung, Taiwan
  • ENYO PHARMA Investigative site TW04
    Kaohsiung, Taiwan
  • ENYO PHARMA Investigative site TW01
    Taipei, Taiwan
  • ENYO PHARMA Investigative site TW02
    Taoyuan, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2021, 12 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 12 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
Apr 28, 2020
StartActual
May 25, 2020
Primary completionActual
Jun 16, 2021
CompletionActual
Nov 29, 2021
Last update
Aug 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04365933
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
May 25, 2020
Primary completion
Jun 16, 2021
Completion
Nov 29, 2021
Last update
Aug 25, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EYP001A · Peginterferon alfa-2a

Start the discussion